Annals of Internal Medicine最新文献

{"title":"Correction: Pharmacologic Treatment of Acute Attacks of Episodic Migraine.","authors":"","doi":"10.7326/ANNALS-25-02645","DOIUrl":"https://doi.org/10.7326/ANNALS-25-02645","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Chronic Urticaria Following HIV mRNA Vaccines: A Challenging Signal in Need of Mechanistic Insight.","authors":"Kimberly G Blumenthal, Elizabeth J Phillips","doi":"10.7326/ANNALS-25-01102","DOIUrl":"10.7326/ANNALS-25-01102","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":"1046-1047"},"PeriodicalIF":19.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143966331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Mortality From Chronic Liver Disease Before, During, and After the COVID-19 Pandemic, 2015 to 2023.","authors":"Donghee Kim, Pojsakorn Danpanichkul, Karn Wijarnpreecha, George Cholankeril, Aijaz Ahmed","doi":"10.7326/ANNALS-24-03218","DOIUrl":"10.7326/ANNALS-24-03218","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":"1054-1057"},"PeriodicalIF":19.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143971450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Embracing Compassion for People Facing Lung Cancer-The American Cancer Society National Lung Cancer Roundtable.","authors":"Jamie L Studts, Lisa Carter-Bawa, Jill Feldman, Joan H Schiller, Elizabeth Scharnetzki, James Pantelas, Eugene Manley, Timothy J Williamson, M Patricia Rivera, Lori C Sakoda, Douglas Wood, Ella A Kazerooni, Lauren S Rosenthal, Robert A Smith, Drew Moghanaki","doi":"10.7326/ANNALS-24-03167","DOIUrl":"10.7326/ANNALS-24-03167","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":"1027-1028"},"PeriodicalIF":19.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144207447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Skeletal Muscle Mass Loss and Glucagon-Like Peptide-1 Receptor Agonists: Are Older Patients at Risk?","authors":"Anjali P Kakkar, Eric Ravussin, Thierry H Le Jemtel","doi":"10.7326/ANNALS-24-03950","DOIUrl":"10.7326/ANNALS-24-03950","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":"1031-1032"},"PeriodicalIF":19.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144257170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Fecal Microbiota Transplantation Versus Vancomycin for Primary <i>Clostridioides difficile</i> Infection : A Randomized Controlled Trial.","authors":"Frederik Emil Juul, Michael Bretthauer, Peter H Johnsen, Faye Samy, Kristian Tonby, Jan Erik Berdal, Dag Arne L Hoff, Eirik H Ofstad, Awet Abraham, Birgitte Seip, Håvard Wiig, Øyvind Bakken Rognstad, Ida F Glad, Jørgen Valeur, Axel E Nissen-Lie, Eivind Ness-Jensen, Kristine M A Lund, Linn K Skjevling, Kurt Hanevik, Hilde Skudal, Ellen J Melsom, Raziye Boyar, Trond J Cooper, Trond E Ranheim, Esben M Riise, Hans-Olov Adami, Mette Kalager, Magnus Løberg, Kjetil K Garborg","doi":"10.7326/ANNALS-24-03285","DOIUrl":"10.7326/ANNALS-24-03285","url":null,"abstract":"<p><strong>Background: </strong>Fecal microbiota transplantation (FMT) is recommended for recurrent <i>Clostridioides difficile</i> infection (CDI), but its role in primary CDI is unclear.</p><p><strong>Objective: </strong>To investigate the efficacy and safety of FMT in primary CDI.</p><p><strong>Design: </strong>Randomized, open-label, noninferiority, multicenter trial. (ClinicalTrials.gov: NCT03796650).</p><p><strong>Setting: </strong>Hospitals and primary care facilities in Norway.</p><p><strong>Patients: </strong>Adults with CDI (<i>C difficile</i> toxin in stool and ≥3 loose stools daily) and no previous CDI within 365 days before enrollment.</p><p><strong>Intervention: </strong>FMT without antibiotic pretreatment versus oral vancomycin, 125 mg 4 times daily for 10 days.</p><p><strong>Measurements: </strong>The primary end point was clinical cure (firm stools or <3 bowel movements daily) at day 14 and no disease recurrence within 60 days with the assigned treatment alone.</p><p><strong>Results: </strong>Of 104 randomly assigned patients, 100 received FMT or the first dose of vancomycin and were eligible for analysis. Clinical cure and no disease recurrence within 60 days without additional treatment was observed in 34 of 51 patients (66.7%) with FMT versus 30 of 49 (61.2%) with vancomycin (difference, 5.4 percentage points [95.2% CI, -13.5 to 24.4 percentage points]; <i>P</i> for noninferiority < 0.001, rejecting the hypothesis that response to FMT is 25 percentage points lower than response to vancomycin). Eleven patients in the FMT group and 4 in the vancomycin group had additional <i>C difficile</i> treatment. Clinical cure at day 14 and no recurrence with or without additional treatment was observed in 40 of 51 patients (78.4%) with FMT and 30 of 49 (61.2%) with vancomycin (difference, 17.2 percentage points [95.2% CI, -0.7 to 35.1 percentage points]). No significant differences in adverse events were observed between groups.</p><p><strong>Limitations: </strong>Open-label design and reliance on clinical end points.</p><p><strong>Conclusion: </strong>FMT may be considered as first-line therapy in primary CDI.</p><p><strong>Primary funding source: </strong>South-East Norway Health Trust.</p>","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":"940-947"},"PeriodicalIF":19.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144309464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"In HF with iron deficiency, IV ferric carboxymaltose did not reduce a composite of first HF hospitalization or CV death at a median 17 mo.","authors":"Dmitry Abramov, Harriette G C Van Spall","doi":"10.7326/ANNALS-25-02297-JC","DOIUrl":"10.7326/ANNALS-25-02297-JC","url":null,"abstract":"<p><strong>Clinical impact ratings: </strong>GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Hematology: [Formula: see text].</p>","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":"JC82"},"PeriodicalIF":19.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does the Patient Want TV?","authors":"Victor S Sloan","doi":"10.7326/ANNALS-25-00658","DOIUrl":"https://doi.org/10.7326/ANNALS-25-00658","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":"178 7","pages":"1050-1051"},"PeriodicalIF":19.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144635948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mammography Screening Preferences Among Screening-Eligible Women in Their 40s.","authors":"Stamatia Destounis, Andrea Arieno","doi":"10.7326/ANNALS-25-01109","DOIUrl":"https://doi.org/10.7326/ANNALS-25-01109","url":null,"abstract":"","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":"178 7","pages":"1060-1061"},"PeriodicalIF":19.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144635952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Medications and Risk for Microscopic Colitis: A Nationwide Study of Older Adults in Sweden.","authors":"Hamed Khalili, Emma E McGee, Prasanna K Challa, Bjorn Roelstraete, Kristina Johnell, Sebastian Schneeweiss, Jonas W Wastesson, Jonas F Ludvigsson","doi":"10.7326/ANNALS-25-00268","DOIUrl":"https://doi.org/10.7326/ANNALS-25-00268","url":null,"abstract":"<p><strong>Background: </strong>Several medications have been identified as potential risk factors for microscopic colitis (MC), but evidence so far is hampered by methodological limitations.</p><p><strong>Objective: </strong>To examine the potential causal effects of previously implicated medications on risk for MC.</p><p><strong>Design: </strong>Emulation of 6 target trials.</p><p><strong>Setting: </strong>Sweden.</p><p><strong>Participants: </strong>All residents in Sweden aged 65 years or older between 2006 and 2017 who met eligibility criteria (<i>n</i> = 191 482 to 2 634 777).</p><p><strong>Measurements: </strong>The primary outcome was biopsy-verified MC. The date of diagnosis was obtained from the nationwide histopathology cohort ESPRESSO (Epidemiology Strengthened by histoPathology Reports in Sweden). Twelve- and 24-month cumulative incidences and absolute risk differences for MC were estimated via inverse probability weighing.</p><p><strong>Results: </strong>The 12- and 24-month cumulative incidences of MC were less than 0.5% under all treatment strategies. Estimated 12-month risk differences were close to null under angiotensin-converting enzyme versus calcium-channel blocker (CCB) initiation, angiotensin-receptor blocker versus CCB initiation, nonsteroidal anti-inflammatory drug initiation versus noninitiation, proton-pump inhibitor initiation versus noninitiation, and statin initiation versus noninitiation. The estimated 12-month risk difference was 0.04% (95% CI, 0.03% to 0.05%) for selective serotonin receptor inhibitors (SSRIs) versus mirtazapine. Results were similar for 24-month risk differences. Several medications were also associated with increased risk for receiving a colonoscopy with a normal colorectal mucosa biopsy result.</p><p><strong>Limitations: </strong>There is possible residual bias due to differential health care utilization or surveillance. Lack of primary care data limited measurement of, and adjustment for, symptoms and medical diagnoses that increase risk for receiving a colonoscopy.</p><p><strong>Conclusion: </strong>No evidence of a causal relationship between most previously suspected pharmacologic triggers and risk for MC was found. Previously reported associations and persistent associations with SSRI initiation may be due to surveillance bias.</p><p><strong>Primary funding source: </strong>The National Institutes of Health and the Swedish Research Council.</p>","PeriodicalId":7932,"journal":{"name":"Annals of Internal Medicine","volume":" ","pages":""},"PeriodicalIF":19.6,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}